Navigation Links
Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011
Date:9/7/2011

PARIS, Sept. 7, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced that its nuclease production capacity has increased ten-fold in 2011, significantly reducing manufacturing costs. Industrialization of the nuclease manufacturing gives Cellectis bioresearch, the genome customization specialist and commercial subsidiary of Cellectis, the potential to supply the technology to approximately 300,000 academic and industrial research laboratories throughout the world. Previously the technology was only used by large industrial groups and laboratories with significant financial resources.

In the last three years, Cellectis has invested significantly to increase its production capacities, growing from 20 nucleases produced in 2008 to a capacity of 7,200 units in 2011, a rate that is expected to continue through 2012.

The use of nucleases by Cellectis' initial customers has demonstrated significant advantages over competitive technologies for creating cell lines for high throughput screening, in a number of diverse applications.

The use of nucleases may also allow, in a near future, researchers to consider Whole Genome Engineering for all kinds of species, and for any application. It is revolutionary change for research, which previously required a gene-by-gene approach.

"Thanks to this dramatic increase in its production capacity, Cellectis is in a very good position for the emerging Whole Genome Engineering calls for tender," said Andre Choulika, Chairman and CEO of Cellectis. "It represents a major technological step-change that we've been targeting for the last 10 years: the high throughput Whole Genome Engineering."

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter: http://twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
5. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
6. Cellectis Unveils Its New Corporate Website
7. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
8. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
9. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
10. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... for Connecticut's innovative, growing companies, today announced the launch of VentureClash , ... (fintech) companies. , “VentureClash looks to attract the best early-stage companies ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... testing technology at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance ... solvents, heavy metals, and more. Expo attendees can stop by booth 1021 to ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief Commercial ... Executive Director and one of the founding commercial leaders responsible for the commercialization ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and ... Symposium as other research and development initiatives for potential stem cell protocol management for ... Stem Cells Group executives began meeting to establish a working agenda and foster initiatives ...
Breaking Biology Technology:
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016  FlexTech, ... in the categories of Innovation, Research & Development, Leadership ... Industry Leadership. This is the 9 th year ... select group of companies and individuals from past ... nominations based on a pre-described set of criteria, by ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 ... to offer Oncimmune,s Early CDT®-Lung, a blood test ... of lung cancer Early CDT®-Lung test to ... --> Early CDT®-Lung test to its clients ... Oncimmune, a leader in early cancer detection, today ...
Breaking Biology News(10 mins):